2018 Alpha-Antitrypsin Deficiency (AATD) Market Report: Insights, Epidemiology and Market Forecasts to 2027 - ResearchAndMarkets.com

DUBLIN--()--The "Alpha-Antitrypsin Deficiency - Market Insights, Epidemiology and Market Forecasts to 2027" drug pipelines has been added to ResearchAndMarkets.com's offering.

The report provides global market share of AATD i.e., 6 Major Markets [United States and EU5 (Germany, Spain, Italy, France and United Kingdom)] and Rest of World (RoW). In 2016, the global market size of AATD was USD 918.78 million.

According to research, the prevalent cases of AATD was 185,860 in 2016 in 6MM. Among 6MM, United States account for highest prevalent cases of AATD with 113,808 prevalent cases in 2016 followed by Germany.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of AATD from 2016 to 2027 segmented by the US, EU-5 countries and Rest of the World (RoW). The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

This market report gives the thorough understanding of the AATD by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for AATD in the US, Europe, and Japan.

Companies Mentioned

  • CSL Behring
  • Grifols
  • Kamada
  • LFB Biotechnologies
  • Shire

Key Topics Covered:

1. Report Introduction

2. Alpha Antitrypsin Deficiency Market Overview at a Glance

3. Disease Background and Overview: Alpha Antitrypsin Deficiency

4. Epidemiology and Patient Population

5. Treatment Algorithm

6. Unmet Needs

7. Marketed Drugs

8. Emerging Therapies

9. Alpha Antitrypsin Deficiency: Global Market Analysis

10. Alpha Antitrypsin Deficiency: Country-Wise Market Analysis

11. Grifols Initiatives towards Alpha Anti-trypsin deficiency

12. USFDA Initiatives for patients with Alpha-1 Antitrypsin Deficiency (AATD)

13. Market Drivers

14. Market Barriers

15. Appendix

16. Report Methodology

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/5k2sz2/2018?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs